Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | PNLIP | P16233 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333350 | 0.81 | MAPK8 (0.48) | HSD11B1FFAR1MRGPRX4PNLIP | |
| SCHEMBL14047189 | 0.80 | HSD11B1 (0.42) | HSD11B1P2RX7ALDH1A1 | |
| SCHEMBL3275691 | 0.77 | SIGMAR1 (0.53) | ALDH1A1 | |
| SCHEMBL3282568 | 0.76 | HSD11B1 (0.41) | HSD11B1TDP1 | |
| SCHEMBL3274504 | 0.76 | KDM4E (0.40) | HSD11B1ALDH1A1 | |
| SCHEMBL942960 | 0.73 | HSD11B1 (0.47) | HSD11B1P2RX7 | |
| SCHEMBL242097 | 0.73 | HSD11B1 (0.43) | HSD11B1ALDH1A1 | |
| SCHEMBL240876 | 0.73 | HSD11B1 (0.43) | HSD11B1ALDH1A1 | |
| SCHEMBL240875 | 0.73 | HSD11B1 (0.43) | HSD11B1ALDH1A1 | |
| SCHEMBL2757124 | 0.73 | HSD11B1 (0.43) | HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152081-B1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| WO-2008127924-A1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137377-A1 | NOVEL COMPOUNDS | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885FFAR1 305/4885SLC6A2 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.